Analysis Of The Mortality Of Russian Patients With Chronic Myeloid Leukaemia In The Multicentre Eutos Eln Population-Based Study (Eutos-Pbs)

Introduction Russia took part in the multicenter population-based Study (Europe) and included 6.8% adult patients (pts) with newly diagnosed chronic myeloid leukemia (CML) (Hoffman V et al. 2016). Objective To analyze the mortality in the Russian cohort of patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in observational study EUTOS PBS. Patients and research methods The analyzed cohort consisted of 197 pts (u003e18 years) with Ph’+/BCR-ABL1+CML diagnosed in period 10/01/2009 - 31/12/2012 from 6 regions of Russia. Phases CML: chronic phase (CP) 93,4%, accelerated phase (AP) + blast crisis (BC) 6%+0,6%. Median (Me) age was 50 (18-82) years, the male/female ratio was equal. Results The Overall Survival (OS) by 5, 6 and 7 years was 80% (95% CI 72–86), 78% (95% CI 65–80) and 73% (95% CI 65–80) correspondingly (p In Russia the study was prolonged with Me follow-up 77 (0,7 – 108) months: 141 (71.5%) pts were alive, 47 (24%) pts died, and the status of 9 (4.5%) pts is was unknown. Forty-seven (23,8%) pts died during the follow-up period. The largest number of deaths was observed in the 1st year after the CML diagnosis: 17 (36%) of 47 cases, 3 of 17 died refusing from the CML treatment. At the 7th year of CML therapy, one pt died after allogenic hematopoietic stem cell transplantation. The causes of death were: 1) progression of CML to AP/BC in 20 (43%) pts, 2) death in remission (in 5 (11%) pts with complete cytogenetic response (CCyR) and/or major molecular response, 3) death without progression to AP/BC but with signs of leukemia in 22 (46%) pts. The 5 years cumulative CI of death from all reasons was 20%, CI of CML-related and CML non-related death at 5th year was 18% and 11% respectively. Conclusion In general, the results of treatment in the Russian non-selected CML pts population sample were comparable with the data of the total European cohort. The CML-related deaths prevailed in the 1st year of CML therapy. The appropriate monitoring and therapy interventions during the 1st year of CML treatment are apparently important for the long-term treatment results.